Forero MNT, Scarparo P, den Dekker W, et al. - Researchers undertook this retrospective single-centre analysis to determine the optimal revascularization strategy for residual coronary stenosis after primary percutaneous coronary intervention among patients who experienced STEMI and multivessel disease (MVD). Participants were categorized into three groups according to the revascularization strategy: 1) CO, 2) ad-hoc MVR and 3) staged MVR. Major adverse cardiac events (MACE) defined as a composite of cardiac mortality, any myocardial infarction and any unplanned revascularization, were compared at a long-term follow-up. At 1,095 days, MACE was reported to be 36.1% for CO, 16.7% for the ad-hoc group and 31% for the staged group. A decreased risk of MACE was achieved with complete revascularization among patients with STEMI and MVD. The strategy that seemed reasonable was ad-hoc MVR as it was associated with lower contrast and stent usage and costs.